Is Agios Pharmaceuticals, Inc. (AGIO) a Buy, Sell, or Hold?
Agios Pharmaceuticals, Inc.
NASDAQ:AGIO
$39.92 USD
-$0.63 (-1.55%)
- Volume
- 672.96K
- Average Volume
- 1.16M
- Market Capitalization
- $2.37B
- P/E Ratio
- -5.51
- Dividend Yield
- 0.00%
- Price Target
- $41.00
- Year High
- $46.00
- Year Low
- $22.24
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $14.19
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Brian Goff |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | AGIO |
| CUSIP | 00847X104 |
| CIK | 0001439222 |
| Web | https://www.agios.com |
| Phone | 617 649 8600 |
| Currency | USD |
| Employees | 540 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.03 |
| Payout Ratio | 0.00 |
| Current Ratio | 14.19 |
| Quick Ratio | 13.59 |
| Cash Ratio | 1.93 |
Sales & Book Value
| Annual Sales | $54.03M |
| Price / Sales | 35.95 |
| Cash Flow | -6.54 |
| Price / Cash Flow | -6.17 |
| Price / Book | 2.12 |
Price Target and Rating
| Average Stock Price Forecast | $41.00 |
| High Stock Price Forecast | $54.00 |
| Low Stock Price Forecast | $32.00 |
| Forecast Upside/Downside | -2.63% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 29 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-7.12 |
| Trailing P/E Ratio | -5.51 |
| PEG Ratio | 0.04 |
| P/E Growth | 0.04 |
| Net Income | $-412.78M |
| Net Margin | -639.84% |
| Pretax Margin | -641.38% |
| Return on Equity | -34.11% |
| Return on Assets | -35.66% |
Financials Score
| AltmanZ Score | 17.95 |
| Piotroski Score | 3.00 |
| Working Capital | 776M |
| Total Assets | 1.18B |
| Ebit | -423.62M |
| Market Cap | 2.41B |
| Total Liabilities | 75.88M |
Poll Results
About Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts. ...
Here's Why Shares in Novo Nordisk Rival, Agios Pharmaceutical, Soared This Week
2026-07-10 07:35:00
Agios stock surged after FDA granted priority review for mitapivat in sickle cell disease. Mitapivat showed mixed Phase 3 results, and competition is coming from Novo Nordisk.
AGIO's Filing for Mitapivat in SCD Gets FDA's Priority Tag, Stock Up
2026-07-08 11:36:15
Agios stock jumps after the FDA accepts and grants priority review to its sNDA for mitapivat in sickle cell disease, with a decision due on Nov. 1, 2026.
Strength Seen in Agios Pharmaceuticals (AGIO): Can Its 17.7% Jump Turn into More Strength?
2026-07-08 11:30:14
Agios Pharmaceuticals (AGIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Here's Why Agios Pharmaceuticals Stock Soared Today (Hint: It's FDA-Related)
2026-07-07 12:32:49
The company took a major step toward an accelerated approval of mitapivat in sickle cell disease today. Agios needs to complete a confirmatory trial before a full traditional approval can be granted.
Why This Novo Nordisk Rival Just Soared Near A Profit-Taking Zone
2026-07-07 11:30:02
Agios stock skyrocketed closer to a profit-taking zone Tuesday after the FDA assigned its sickle cell drug a speedy review.
U.S. FDA Grants Priority Review to Agios' sNDA for Mitapivat in Sickle Cell Disease
2026-07-07 07:00:00
FDA's PDUFA goal date is November 1, 2026 If approved, mitapivat is positioned to become the first oral PK activator for patients with sickle cell disease CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for mitapivat, an oral pyruvate kinase (PK) activator, in sickle cell disease with a Priority Review.
2026-06-29 07:00:00
CAMBRIDGE, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the company will host a conference call and live webcast on Thursday, July 30, 2026, at 8:00 a.m.
AGIO Stock Surges 35% in Six Months: What's Driving It?
2026-06-18 12:25:15
Agios' shares rose 35% in six months as Aqvesme gains traction, mitapivat expands globally and new ITP rights add to its rare blood disease push.
Frequently Asked Questions
-
What is the current Agios Pharmaceuticals, Inc. (AGIO) stock price?
-
Agios Pharmaceuticals, Inc.(NASDAQ:AGIO) stock price is $39.92 in the last trading session. During the trading session, AGIO stock reached the peak price of $46 while $22.24 was the lowest point it dropped to. The percentage change in AGIO stock occurred in the recent session was --1.55% while the dollar amount for the price change in AGIO stock was -$-0.63.
-
AGIO's industry and sector of operation?
-
The NASDAQ listed AGIO is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of AGIO?
-
Craig Thompson | Co-Founder
Cecilia Jones | Chief Financial Officer
Tak Wah Mak FRSC | Co-Founder
James William Burns | Chief Legal Officer
T. J. Washburn | Vice President, Controller & Principal Accounting Officer -
How many employees does AGIO have?
-
Number of AGIO employees currently stands at 540. AGIO operates from 88 Sidney Street, Cambridge, MA 02139-4169, US.
-
Link for AGIO official website?
-
Official Website of AGIO is: https://www.agios.com
-
How do I contact AGIO?
-
AGIO could be contacted at phone #617 649 8600 and can also be accessed through its website. AGIO operates from 88 Sidney Street, Cambridge, MA 02139-4169, US.
-
How many shares of AGIO are traded daily?
-
The average number of AGIO shares traded daily for last 3 months was 1.16M.
-
What is the market cap of AGIO currently?
-
The market value of AGIO currently stands at $2.37B with its latest stock price at $39.92